Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Leede Financial upped their FY2025 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, July 9th. Leede Financial analyst D. Loe now anticipates that the company will earn ($0.37) per share for the year, up from their prior estimate of ($0.40). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech's FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.36) EPS, FY2028 earnings at ($0.36) EPS and FY2029 earnings at ($0.25) EPS.
Separately, Jones Trading lowered Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
View Our Latest Analysis on ONC
Oncolytics Biotech Trading Down 6.2%
TSE ONC opened at C$1.51 on Friday. Oncolytics Biotech has a 12 month low of C$0.44 and a 12 month high of C$2.08. The firm has a market capitalization of C$116.38 million, a P/E ratio of -4.21 and a beta of 1.35. The business has a fifty day simple moving average of C$0.81 and a 200 day simple moving average of C$0.94. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
